• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, October 27, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

VATS Tops Chest Tubes in Pediatric Empyema Review, but Evidence Stays Weak

by
October 27, 2026
in Health
Reading Time: 3 mins read
0
VATS Tops Chest Tubes in Pediatric Empyema Review, but Evidence Stays Weak

VATS Tops Chest Tubes in Pediatric Empyema Review, but Evidence Stays Weak

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A large systematic review comparing the four main treatments for empyema thoracis in children has found that video-assisted thoracoscopic surgery, or VATS, was associated with fewer treatment escalations and shorter treatment durations than chest tube drainage alone, though the authors caution that most of the underlying evidence is observational and of low certainty. Clinicians can manage it with a chest tube alone, a chest tube plus fibrinolytic drugs that dissolve the fluid, VATS, or open thoracotomy. Which strategy works best has remained uncertain, prompting researchers from Mohammed Bin Rashid University of Medicine and Health Sciences and Mediclinic Parkview Hospital in Dubai to conduct the review, which was prospectively registered with PROSPERO.

The team searched PubMed, Embase, Scopus, Web of Science and the CENTRAL database for studies published from January 2000 through January 2026 involving children under 18 years of age. They identified 77 studies covering 7,378 children. Using random-effects pairwise and frequentist network meta-analyses, they compared chest tube alone, chest tube with fibrinolytics, VATS and thoracotomy across several outcomes.

The primary outcome was hospital length of stay. Secondary outcomes included treatment escalation, treatment success, complications, mortality and treatment-related durations. Treatments were ranked using P-scores, and a sensitivity analysis restricted the network to arms in which the intervention was given as the first-line treatment.

Risk of bias was assessed with ROBINS-I, RoB 2 or the JBI checklist depending on study design, and certainty was graded with the GRADE framework. Compared with a chest tube alone, treatment escalation was lower with VATS, with a relative risk of 0.17 (95% confidence interval 0.07 to 0.37), lower with thoracotomy (RR 0.13, 95% CI 0.04 to 0.36), and lower with chest tube plus fibrinolytics (RR 0.48, 95% CI 0.26 to 0.89). Certainty was moderate for three of the six escalation comparisons and low or very low elsewhere.

VATS was also associated with shorter pleural drainage, by a mean difference of 2.54 days (95% CI 4.64 to 0.44 days fewer), shorter antibiotic duration by 4.95 days (95% CI 9.36 to 0.54 days fewer), and shorter fever duration by 2.00 days (95% CI 3.97 to 0.04 days fewer). Notably, VATS did not significantly shorten overall hospital length of stay, with a mean difference of 2.06 days (95% CI 4.57 fewer to 0.45 more). In the pairwise analysis, escalation was higher with chest tube plus fibrinolytics than with VATS, with a relative risk of 3.18 (95% CI 1.45 to 6.96).

The sensitivity analysis restricted to primary-line arms preserved these associations, but a higher network mortality estimate with thoracotomy lost statistical significance, suggesting that this finding was sensitive to how treatment lines were defined. Exploratory mean P-scores ranked VATS highest at 0.74, followed by thoracotomy at 0.50, chest tube plus fibrinolytics at 0.47, and chest tube alone at 0.29. These rankings, however, are exploratory summaries of the network rather than definitive statements about which treatment should come first in clinical practice.

The authors conclude that chest tube drainage alone was associated with more escalation than each alternative, while VATS was associated with shorter treatment-related durations. But they emphasize that the evidence is predominantly observational and of low to very low certainty for most comparisons, and that estimates involving thoracotomy were sensitive to treatment line. The associations are described as hypothesis-generating and do not establish a treatment hierarchy.

According to the review, trials with explicit disease staging and standardized definitions of treatment escalation are needed before firm conclusions can be drawn about the optimal strategy for children with this serious pneumonia complication.

Subject of Research: Comparative effectiveness of chest tube, fibrinolytics, VATS and thoracotomy for pediatric empyema thoracis

Article Title: Comparative effectiveness of treatment strategies for pediatric empyema thoracis: a systematic review with pairwise and network meta-analyses

Article References: Alhusami, M. A., Senjab, K., Alabdullah, M., Malik, M., Kanj, S., Kanj, L., & Naji, H. (2026). Comparative effectiveness of treatment strategies for pediatric empyema thoracis: a systematic review with pairwise and network meta-analyses. Frontiers in Pediatrics, 14, Article 1980275. https://doi.org/10.3389/fped.2026.1980275

Image Credits: AI Generated

DOI: 10.3389/fped.2026.1980275

Keywords: pediatric empyema, systematic review, network meta-analysis, VATS, chest tube drainage, intrapleural fibrinolysis, thoracotomy, treatment escalation, hospital length of stay, GRADE certainty, Comparative, effectiveness

News Source: Harold Sullivan. (October 26, 2026). VATS Tops Chest Tubes in Pediatric Empyema Review, but Evidence Stays Weak. Scienmag.

Tags: chest tube drainageComparativeeffectivenessGRADE certaintyhospital length of stayintrapleural fibrinolysisNetwork Meta-Analysispediatric empyemasystematic reviewthoracotomytreatment escalationVATS
Share12Tweet7Share2ShareShareShare1

Related Posts

Why Public Health Leaders Must Own AI Risk Decisions Now

Why Public Health Leaders Must Own AI Risk Decisions Now

October 27, 2026
Rare Neuroblastoma Component Found in Infant's Testicular Teratoma

Rare Neuroblastoma Component Found in Infant’s Testicular Teratoma

October 27, 2026

Rare Cerebral Air Embolism Strikes Woman During Routine Eye Surgery

October 27, 2026

New chimeric antibodies turn marmosets into a working KSHV infection model

October 27, 2026

POPULAR NEWS

  • Enzyme-Induced Carbonate Precipitation Strengthens Red Clay Against Wetting–Drying Damage

    Enzyme-Induced Carbonate Precipitation Strengthens Red Clay Against Wetting–Drying Damage

    29 shares
    Share 12 Tweet 7
  • Seasonal Shifts in Pathogenic Microbes Mapped in the South China Sea

    29 shares
    Share 12 Tweet 7
  • Optimizing Epoxy Nanocomposites for Stronger, Water-Resistant Electrical Insulation

    29 shares
    Share 12 Tweet 7
  • Why Public Health Leaders Must Own AI Risk Decisions Now

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Enzyme-Induced Carbonate Precipitation Strengthens Red Clay Against Wetting–Drying Damage

Seasonal Shifts in Pathogenic Microbes Mapped in the South China Sea

Optimizing Epoxy Nanocomposites for Stronger, Water-Resistant Electrical Insulation

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.